Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > BUSINESS
BUSINESS
- Maribavir Hits Primary Goal for Post-Transplant CMV Infection: Takeda
December 8, 2020
- Kobayashi Kako Launches Another Recall for Itraconazole, Class II This Time
December 8, 2020
- Astellas in Oncolytic Virus Deal with KaliVir
December 8, 2020
- Astellas, Viatris Wind Up Japan Celecox Copromotion at December-End
December 8, 2020
- Kyle Tattle to Take Reins of MSD Japan from January
December 8, 2020
- Teijin Pharma’s Spasticity Med Xeomin Now Available
December 7, 2020
- Keytruda Top Seller for 4 Months Running: Encise
December 7, 2020
- Ex-Janssen Exec Rami Suzuki to Lead Ferring Japan
December 7, 2020
- Kobayashi Kako Recalls Itraconazole over Hypnotic Contamination; Side Effects Confirmed
December 7, 2020
- 26 Japan Drug Makers Barely Avoid Revenue Decline in H1 FY2020 Despite Price Cuts, COVID-19: Tally
December 4, 2020
- Sandoz to Discontinue Filgrastim Biosimilars; Late Market Entry a Factor
December 4, 2020
- 2 More Soft Bag Products Recalled Over Flawed Testing at Kyowa CritiCare
December 3, 2020
- Telomelysin Triplet Enters Japan PI for HCC: Oncolys
December 3, 2020
- Janssen Files SC Injection of Darzalex/Vorhyaluronidase Alfa for AL Amyloidosis in Japan
December 3, 2020
- Crysvita Now Available for Self-Injection in Japan: Kyowa Kirin
December 2, 2020
- Hirosaki University to Test StemRIM’s Redasemtide for Knee Osteoarthritis
December 2, 2020
- Sosei Licenses CGRP Antagonists to Biohaven
December 2, 2020
- Japan’s 1st Therapeutic App Now Available: CureApp
December 2, 2020
- Takeda Closes Sale of 18 Non-Core Meds to Celltrion in Asia-Pacific
December 2, 2020
- 1st Patient Enrolled in Adoptive Trial by Amgen, Takeda, UCB: COVID R&D Alliance
December 2, 2020
ページ
More than a year after Dupixent (dupilumab) became the first antibody therapy approved for COPD in Japan, drug makers are…
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…